Adult patients (n=144) with isocitrate dehydrogenase (IDH)-wildtype glioblastoma will be included, who, at least ≥3 months after the concomitant phase of standard temozolomide-based chemoradiation, have new or increased contrast enhancement on MRI, causing doubt between tumor growth or pseudoprogression. This evidence concerns the gene IDH3A and neoplasm.